Tucatinib Patent Expiration
Tucatinib is Used for treating advanced or metastatic colorectal cancer and breast cancer that is HER2-positive or overexpressing. It was first introduced by Seagen Inc
Tucatinib Patents
Given below is the list of patents protecting Tucatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tukysa | US11207324 | Treatment of HER2 positive cancers | Apr 27, 2038 | Seagen |
| Tukysa | US11666572 | Treatment of HER2 positive cancers | Apr 27, 2038 | Seagen |
| Tukysa | US12048698 | Treatment of HER2 positive cancers | Apr 27, 2038 | Seagen |
| Tukysa | US11504370 | Treatment of brain cancer | Mar 25, 2033 | Seagen |
| Tukysa | US9457093 | Solid dispersions of a ERB2 (HER2) inhibitor | Oct 12, 2032 | Seagen |
| Tukysa | US8648087 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | Apr 12, 2031 | Seagen |
| Tukysa | US9693989 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | May 09, 2027 | Seagen |
| Tukysa | US7452895 | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Nov 16, 2024
(Expired) | Seagen |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tucatinib's patents.
Latest Legal Activities on Tucatinib's Patents
Given below is the list recent legal activities going on the following patents of Tucatinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Pre-Exam Notice | 29 May, 2024 | US9693989 |
| Email Notification Critical | 29 May, 2024 | US9693989 |
| Change in Power of Attorney (May Include Associate POA) Critical | 29 May, 2024 | US9693989 |
| Patent eCofC Notification | 16 Apr, 2024 | US11666572 |
| Email Notification Critical | 16 Apr, 2024 | US11666572 |
| Mail Patent eCofC Notification | 16 Apr, 2024 | US11666572 |
| Recordation of Patent eCertificate of Correction | 16 Apr, 2024 | US11666572 |
| Post Issue Communication - Certificate of Correction | 29 Mar, 2024 | US11666572 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Mar, 2024 | US9457093 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US8648087 |
Tucatinib's Family Patents
